Shaping A Shkreli Bill: Voucher Abuse Solution May Stumble On FDA Effects

House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.

Efforts to prevent another Martin Shkreli-like abuse of FDA incentives are proving difficult, in part because of the potential effects on the US agency.

The Biotechnology Innovation Organization warned a proposed tweak to the tropical disease priority review voucher program intended to ensure a...